Axitinib

What is Axitinib?

Axitinib is a prescription medication primarily used for the treatment of advanced kidney cancer, specifically renal cell carcinoma (RCC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which are a type of targeted therapy. Axitinib works by blocking specific proteins essential for tumor growth and the formation of blood vessels that supply tumors, effectively starving the cancer. Marketed as Inlyta, Axitinib represents a significant advancement in cancer treatment, offering a crucial option for patients with advanced RCC who have progressed on prior therapies.

How Does it Work?

The mechanism of action of Axitinib focuses on its ability to selectively inhibit multiple receptor tyrosine kinases (RTKs) involved in tumor angiogenesis and growth. It potently inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3. These VEGFRs are critical for angiogenesis (new blood vessel formation), which tumors exploit to grow and spread. By blocking these receptors, Axitinib disrupts signaling pathways that promote endothelial cell proliferation and survival, thereby inhibiting new blood vessel formation and reducing blood supply to the tumor. This anti-angiogenic effect starves the tumor, hindering its growth and spread. This precise action makes it a valuable tyrosine kinase inhibitor in cancer therapy.

Medical Uses

Axitinib is primarily approved for the treatment of advanced renal cell carcinoma (RCC).

• Second-line treatment: It is often used in patients who have already received one prior systemic therapy for advanced RCC and whose disease has progressed.
• First-line treatment (in combination): In some regions, Axitinib is also approved for first-line treatment of advanced RCC when combined with an immune checkpoint inhibitor, such as pembrolizumab. This combination has shown superior efficacy in certain patient populations.

Axitinib's targeted approach makes it a crucial component in the evolving landscape of kidney cancer treatment.

Dosage

The dosage of Axitinib is highly individualized and determined by a healthcare professional.

• Standard Starting Dose: The typical recommended starting dose is 5 mg orally twice daily, approximately 12 hours apart, with or without food.
• Dose Adjustments: Doses may be adjusted upwards (e.g., to 7 mg, 8 mg, 9 mg, or 10 mg twice daily) based on tolerability and blood pressure response, provided blood pressure remains below 150/90 mmHg. Conversely, doses may be reduced (e.g., to 3 mg or 2 mg twice daily) if severe side effects occur.
• Administration: Take Axitinib exactly as prescribed. Do not take a missed dose close to the next scheduled dose. Regular monitoring of blood pressure and other potential side effects is essential.

Side Effects

Like all medications, Axitinib can cause side effects. The most common are often manageable but require monitoring.

• Common Side Effects: Hypertension (high blood pressure), diarrhea, fatigue, nausea, vomiting, decreased appetite, hand-foot syndrome, weight loss, headache, dysphonia (hoarseness), and proteinuria.
• Serious Side Effects (require immediate medical attention): Blood clots (e.g., stroke, heart attack), bleeding events (e.g., gastrointestinal hemorrhage), thyroid dysfunction, gastrointestinal perforation, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), and liver problems.

Patients should report any new or worsening symptoms to their doctor promptly. Regular blood pressure monitoring and blood tests are crucial during Axitinib therapy.

Drug Interactions

Axitinib is primarily metabolized by the cytochrome P450 3A4/5 (CYP3A4/5) enzyme system. This means it can interact with other medications affecting this system.

• Strong CYP3A4/5 Inhibitors: Co-administration with strong inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can significantly increase Axitinib levels, potentially leading to increased toxicity. A dose reduction of Axitinib may be necessary.
• Strong CYP3A4/5 Inducers: Co-administration with strong inducers (e.g., rifampin, carbamazepine, St. John's Wort) can decrease Axitinib levels, potentially reducing efficacy. A dose adjustment of Axitinib may be necessary.
• Other Medications: Caution is advised with drugs that prolong the QT interval or increase bleeding risk.

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid dangerous interactions.

FAQ

• Q: Is Axitinib chemotherapy?
  • A: No, Axitinib is not traditional chemotherapy. It is a targeted therapy, specifically a tyrosine kinase inhibitor, working by blocking specific pathways in cancer growth and blood vessel formation, rather than broadly killing rapidly dividing cells.
• Q: How long is Axitinib treatment?
  • A: Treatment typically continues as long as the patient benefits and tolerates the side effects. The duration is determined by the treating physician.
• Q: Can I take Axitinib with food?
  • A: Axitinib can be taken with or without food. Consistency (always with or always without) is important for consistent absorption. Avoid grapefruit products.
• Q: What if I miss a dose?
  • A: If you miss a dose of Axitinib, do not take it if it's close to your next scheduled dose. Just take your next dose at the regular time. Do not double doses.

Products containing Axitinib are available through trusted online pharmacies. You can browse Axitinib-based medications at ShipperVIP or Medicenter.

Summary

Axitinib is a vital targeted therapy and tyrosine kinase inhibitor for advanced renal cell carcinoma. By inhibiting VEGFRs, it disrupts tumor angiogenesis, hindering cancer growth. While generally well-tolerated, it carries common side effects like hypertension and diarrhea, and serious risks such as bleeding or thrombotic events. Careful dosage management, diligent monitoring, and awareness of drug interactions are crucial. As part of a comprehensive cancer treatment strategy, Axitinib offers a valuable option, improving prognosis and quality of life for patients.